Product information and disease descriptionPlace of product in therapyApproaches to treatment
Current treatment options and standard of care
47 evidence topics · 34 sources
Lirafugratinib (Lyrfigtu)
Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma
- Manufacturer
- Elevar Therapeutics
- Regulatory submission
- NDA submitted January 2026
- Last updated